REXTOVY Drug Patent Profile
✉ Email this page to a colleague
When do Rextovy patents expire, and what generic alternatives are available?
Rextovy is a drug marketed by Amphastar Pharms Inc and is included in one NDA.
The generic ingredient in REXTOVY is naloxone hydrochloride. There is one drug master file entry for this compound. Forty-eight suppliers are listed for this compound. Additional details are available on the naloxone hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Rextovy
A generic version of REXTOVY was approved as naloxone hydrochloride by HOSPIRA on September 24th, 1986.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for REXTOVY?
- What are the global sales for REXTOVY?
- What is Average Wholesale Price for REXTOVY?
Summary for REXTOVY
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| What excipients (inactive ingredients) are in REXTOVY? | REXTOVY excipients list |
| DailyMed Link: | REXTOVY at DailyMed |
Pharmacology for REXTOVY
| Drug Class | Opioid Antagonist |
| Mechanism of Action | Opioid Antagonists |
US Patents and Regulatory Information for REXTOVY
REXTOVY is protected by zero US patents and one FDA Regulatory Exclusivity.
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Amphastar Pharms Inc | REXTOVY | naloxone hydrochloride | SPRAY, METERED;NASAL | 208969-001 | Mar 7, 2023 | OTC | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
